Retatrutide 10mg Vial

Last updated: July 2026

Retatrutide 10mg is a research-grade triple-agonist peptide that targets three metabolic hormone receptors — Glucagon-Like Peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon. Eli Lilly developed the compound as an investigational treatment for weight loss, and in trials it is dosed once weekly via subcutaneous injection after reconstitution with bacteriostatic water. This guide covers dosage, benefits, and how to use retatrutide 10mg, with specific attention to South African buyers.

By the end of this article, you will:

• Understand how retatrutide's triple-agonist mechanism drives weight loss.
• Know the standard dose escalation schedule and reconstitution steps.
• See how retatrutide compares to semaglutide and tirzepatide, including risks and regulatory status in South Africa.

Key Takeaways

• Mechanism: Retatrutide (LY3437943) is a 39-amino-acid triple hormone receptor agonist developed by Eli Lilly (Coskun et al., Cell Metabolism 2022).
• Efficacy: Participants assigned to the 12 mg dose lost a mean 24.2% of body weight over 48 weeks in a Phase 2 trial (Jastreboff et al., NEJM 2023).
• Dosing: Once weekly; an approximately 6-day half-life supports weekly administration.
• Reconstitution: Mix with bacteriostatic water; refrigerate at 2–8°C after mixing.
• South Africa status: Not registered with the South African Health Products Regulatory Authority (SAHPRA); sold for research use only (SAHPRA).
• Risks: Gastrointestinal side effects, raised heart rate, and class-wide pancreatitis concerns require medical oversight.

This guide unpacks each step with clinical data and practical instruction.

What Is Retatrutide? The Triple Agonist Explained

Retatrutide (LY3437943, CAS 2381089-83-2) is a synthetic peptide developed by Eli Lilly. Retatrutide activates three metabolic hormone receptors at the same time — GLP-1, GIP, and glucagon — making it the first triple agonist peptide to reach late-stage obesity trials (Coskun et al., Cell Metabolism 2022).

As an incretin mimetic (a synthetic compound that copies natural gut hormones controlling insulin and appetite), retatrutide ships as a lyophilised peptide — a freeze-dried powder. You must reconstitute the powder with bacteriostatic water before subcutaneous injection.

The triple-receptor mechanism separates retatrutide from existing weight-loss peptides:

1. Semaglutide (Ozempic, Wegovy) — single agonist. Targets GLP-1 only, suppressing appetite and slowing gastric emptying. Available locally as HD Labs Semaglutide 10.
2. Tirzepatide (Mounjaro, Zepbound) — dual agonist. Targets GLP-1 + GIP, adding insulin sensitivity benefits to appetite control.
3. Retatrutide — triple agonist. Targets GLP-1 + GIP + glucagon, adding hepatic energy expenditure and lipolysis (fat breakdown) on top of appetite suppression.

Glucagon receptor activation is the key differentiator. Semaglutide and tirzepatide reduce calorie intake. Retatrutide reduces intake and is proposed to increase output by stimulating fat oxidation in the liver, which raises energy use at rest. This dual-pronged action (less in, more out) is the mechanism behind the 24.2% mean weight loss seen at 48 weeks in the 12 mg arm of the Phase 2 trial (Jastreboff et al., NEJM 2023).

Some buyers worry that a stronger mechanism means harsher side effects. In the Phase 2 trial, gastrointestinal side effects were dose-related and broadly consistent with the wider GLP-1 drug class when users followed a slow titration schedule (covered below).

Vial or pen format?

Most South African buyers choose the 10mg vial for dose flexibility. A single vial covers multiple titration weeks at lower starter doses. The Body Pharm Retatrutide 32 Pen offers a pre-measured alternative. Users preferring a dual agonist can compare the Body Pharm Tirzepatide 60 Pen.

How Retatrutide Works: GLP-1, GIP & Glucagon

Retatrutide produces weight loss by activating three metabolic receptors at once. Together, these receptors control how much you eat, how efficiently you process glucose, and how much energy you burn at rest.

1. GLP-1 receptor (appetite & satiety) — Slows gastric emptying and signals fullness to the hypothalamus, reducing hunger and meal size. Semaglutide uses this same pathway (Coskun et al., Cell Metabolism 2022).
2. GIP receptor (insulin sensitivity & fat handling) — Enhances glucose-dependent insulin secretion and influences how adipose tissue stores and releases fat. GIP activity is thought to reduce the metabolic resistance that frequently stalls weight loss on GLP-1-only drugs.
3. Glucagon receptor (energy expenditure & lipolysis) — Stimulates hepatic fat oxidation and raises basal metabolic rate, so the body burns more calories at rest. Semaglutide and tirzepatide lack this mechanism.

Why the triple combination matters

GLP-1 and GIP reduce energy intake. Glucagon increases energy output. Combining all three is proposed to create a synergistic deficit — less in, more out — that single- and dual-agonists cannot replicate.

The clinical signal from the Phase 2 trial is strong. Participants assigned to the 12 mg dose lost a mean 24.2% of body weight over 48 weeks, compared with 2.1% on placebo (Jastreboff et al., NEJM 2023). For context, semaglutide reached about 15% in its Phase 3 obesity trial and tirzepatide about 22.5% in its own trial; these are cross-trial comparisons rather than head-to-head data, but they position retatrutide among the most effective weight-loss compounds studied to date.

Some readers will reasonably ask whether stronger weight loss means higher rebound risk. Phase 3 trials are still in progress, so long-term maintenance data is limited and warrants caution.

Users who prefer dual-agonist therapy can review the Body Pharm Tirzepatide 60 Pen as a comparison.

Retatrutide Dosage Guide for Weight Loss

In the Phase 2 trial, retatrutide was dosed once weekly via subcutaneous injection. A gradual titration schedule minimises gastrointestinal side effects and builds tolerance to the triple-agonist activity. Below is a representative dose escalation protocol reflecting the higher-dose arm of that trial (Jastreboff et al., NEJM 2023):

1. Weeks 1–4: 2 mg/week — Starting dose to assess tolerance. Nausea and mild gastrointestinal symptoms are most common during this phase; the trial found a 2 mg start was better tolerated than a 4 mg start.
2. Weeks 5–8: 4 mg/week — First escalation. Participants whose target dose was 4 mg lost a mean 17.1% of body weight at 48 weeks.
3. Weeks 9–12: 8 mg/week — Advance only if the 4 mg dose is well tolerated. Participants whose target dose was 8 mg lost a mean 22.8% at 48 weeks.
4. Week 13 onward: 12 mg/week (maximum studied dose) — Reserved for users seeking maximum efficacy. The 12 mg target group lost a mean 24.2% of body weight at 48 weeks.
5. Maintenance — Once a target weight is reached, users typically hold at their effective dose rather than escalating further. Additional dose increases raise side-effect burden without proportional benefit.

Why slow titration matters

Gastrointestinal adverse events in the trial were dose-related and clustered during escalation, so adverse-event-related dose reductions were more common in the higher-dose arms; a lower 2 mg starting dose partially mitigated these effects (Jastreboff et al., NEJM 2023). Climbing slowly is the single biggest factor in staying on therapy long enough to see results.

A common concern is impatience with the slow start. Skipping titration weeks sharply increases the risk of severe nausea and dropout, which delays results far more than a measured ramp-up.

Vial efficiency at lower doses

A 10 mg vial supports five full 2 mg starter doses, or two 4 mg doses with 2 mg to spare. The vial covers the early titration weeks in a single unit and provides a cost-effective entry point before progressing to higher doses. Users preferring a pre-measured format can compare the Body Pharm Retatrutide 32 Pen.

A qualified healthcare provider familiar with incretin therapies and your medical history must guide your dosing.

Retatrutide Dosage Escalation Table

A representative escalation schedule based on the Phase 2 trial breaks down as follows (Jastreboff et al., NEJM 2023):

Week Range	Weekly Dose	Notes
Weeks 1–4	2 mg	Starting dose; assess tolerance and gastrointestinal response
Weeks 5–8	4 mg	Increase if gastrointestinal side effects are manageable (4 mg target group: 17.1% mean loss at 48 weeks)
Weeks 9–12	8 mg	Maintenance or further escalation (8 mg target group: 22.8% mean loss at 48 weeks)
Week 13+	Up to 12 mg	Maximum studied dose, under medical supervision (12 mg target group: 24.2% mean loss at 48 weeks)

What's in the Retatrutide 10mg Vial?

Each retatrutide vial contains 10 mg of lyophilised (freeze-dried) retatrutide peptide (CAS 2381089-83-2) sealed under sterile conditions. Suppliers provide a 2 ml ampule of bacteriostatic water alongside the vial for reconstitution. The lyophilised powder format is the standard presentation for an investigational peptide of this type: a freeze-dried solid that is reconstituted into solution immediately before subcutaneous injection.

Lyophilisation removes water from the peptide and locks it into a stable solid state. This stability lets the peptide survive international shipping under cool-pack conditions without degradation — an important property for a synthetic incretin peptide (Coskun et al., Cell Metabolism 2022). Once reconstituted, you administer the solution via subcutaneous injection into the abdomen, thigh, or upper arm.

Buyers often ask whether the powder format affects potency. As long as you store and reconstitute the vial correctly (steps below), the dissolved peptide matches the activity of pre-mixed pen formats.

Storage Requirements

• Unopened lyophilised vial: store at -20°C for long-term stability, or 2–8°C for short-term (several weeks) under standard cold-chain peptide-handling practice.
• Reconstituted solution: refrigerate at 2–8°C, protect from light, and use within 28 days.

Buyers preferring a pre-filled format can compare the Body Pharm Retatrutide 32 Pen as an alternative to vial reconstitution.

How to Reconstitute and Inject Retatrutide 10mg

Reconstituting a 10 mg vial with 2 ml of bacteriostatic water yields a concentration of 5 mg/ml. Every 0.1 ml on an insulin syringe equals 0.5 mg of retatrutide. Follow the eight steps below to prepare and inject the dose.

1. Gather supplies: the lyophilised retatrutide 10mg vial, the 2 ml ampule of bacteriostatic water (0.9% benzyl alcohol), 29–31 gauge insulin syringes (1 ml / 100-unit), alcohol swabs, and a sharps container.
2. Sanitise: wipe the rubber stopper of both the retatrutide vial and the bacteriostatic water with a fresh alcohol swab and let the stopper air-dry.
3. Draw diluent: withdraw 2 ml of bacteriostatic water into a syringe.
4. Add slowly: inject the water down the inside wall of the retatrutide vial — never directly onto the powder pellet. Do not shake.
5. Dissolve: swirl gently for 10–20 seconds until the solution turns completely clear and colourless. Discard if cloudy or particulate.
6. Draw your dose: for a 2 mg starting dose, draw to the 0.4 ml (40-unit) mark. For 4 mg, draw 0.8 ml (80 units). One vial therefore covers roughly five weekly 2 mg injections during titration.
7. Inject subcutaneously: pinch a fold of skin on the abdomen (≥5 cm from the navel), outer thigh, or upper arm, insert at 90°, and depress slowly. Rotate sites weekly to prevent lipohypertrophy (lumpy fat tissue from repeated injections).
8. Store and label: refrigerate the vial at 2–8°C, protect the vial from light, write the reconstitution date on the label, and use within 28 days.

First-time injectors often worry about pain or technique errors. Insulin syringes use ultra-fine 29–31 gauge needles, and most users report only minor pinching. Should the powder fail to dissolve fully, do not inject — discard the vial.

Users who prefer to skip reconstitution entirely can opt for the pre-mixed Body Pharm Retatrutide 32 Pen, which delivers metered doses without syringe maths.

Retatrutide Benefits: What the Research Shows

Retatrutide produced some of the largest weight reductions recorded in a published pharmacological obesity trial to date. Simultaneous activation of three metabolic receptors is proposed to drive this effect. The Jastreboff et al. 2023 NEJM Phase 2 randomised trial (n=338, 48 weeks) reported the following mean body weight changes from baseline (Jastreboff et al., NEJM 2023):

1. Placebo: −2.1%
2. 1 mg retatrutide: −8.7%
3. 4 mg retatrutide: −17.1%
4. 8 mg retatrutide: −22.8%
5. 12 mg retatrutide: −24.2%

Why the triple-agonist mechanism is proposed to outperform dual agonists

GLP-1 receptor activation slows gastric emptying and suppresses appetite. GIP improves insulin sensitivity and glucose homeostasis (Coskun et al., Cell Metabolism 2022). The third arm — glucagon receptor agonism — is proposed to increase resting energy expenditure and lipolysis. This third mechanism is the theorised edge over the dual-agonist Body Pharm Tirzepatide 60 Pen.

Beyond weight loss

Phase 2 data also showed reductions in visceral adiposity, improved haemoglobin A1c (HbA1c, a measure of average blood sugar), lower triglycerides, and improved blood pressure (Jastreboff et al., NEJM 2023). A dedicated cardiovascular and kidney outcomes trial is underway under Eli Lilly's TRIUMPH programme (ClinicalTrials.gov NCT06383390).

Readers should weigh these benefits against the regulatory reality. Retatrutide remains an investigational compound in Phase 3 trials, and the FDA, EMA, and SAHPRA have not approved it. These are research findings, not approved indications.

Retatrutide Side Effects & Safety Considerations

Retatrutide's side effect profile mirrors the broader GLP-1 receptor agonist class. Gastrointestinal effects dominate and proved manageable through gradual dose titration in the Phase 2 trial (Jastreboff et al., NEJM 2023).

Most common side effects

Gastrointestinal symptoms — nausea, vomiting, diarrhoea, constipation, and decreased appetite — were the most frequently reported events in the Phase 2 trial. These events were dose-related, were mostly mild to moderate in severity, occurred predominantly during dose escalation, and were partially mitigated by starting at a lower 2 mg dose rather than 4 mg (Jastreboff et al., NEJM 2023). Gastrointestinal effects were the main reason for dose adjustment, which supports a slow titration approach.

Rare but serious risks

Pancreatitis remains a theoretical class-wide concern for incretin-based therapies, though the Phase 2 data did not show elevated rates. The glucagon-receptor activity warrants additional caution around heart rate — the trial reported dose-dependent increases in heart rate that peaked at 24 weeks and declined thereafter (Jastreboff et al., NEJM 2023) — and around hepatic markers, because glucagon-receptor activity affects cardiac output and liver enzyme turnover.

Contraindications

Anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), pregnancy, or active pancreatic disease should avoid retatrutide. Users worried about cardiovascular side effects should discuss baseline heart rate and blood pressure monitoring with their provider before starting. Users considering a dual-agonist alternative may review the Body Pharm Tirzepatide 60 Pen. Always consult a licensed healthcare provider before starting any peptide protocol.

Retatrutide vs Tirzepatide vs Semaglutide: Key Differences

In trial data, retatrutide produced larger mean weight loss than the figures reported for tirzepatide and semaglutide in their respective trials, attributed to activation of a third receptor — glucagon — that is proposed to drive additional energy expenditure beyond appetite suppression alone. These are cross-trial comparisons, not head-to-head results.

Peptide	Receptors	Max Weight Loss	Approval
Semaglutide (Ozempic/Wegovy)	GLP-1	14.9% at 68 weeks (STEP-1)	FDA & EMA approved
Tirzepatide (Mounjaro/Zepbound)	GLP-1 + GIP	22.5% at 72 weeks (SURMOUNT-1)	FDA & EMA approved
Retatrutide	GLP-1 + GIP + Glucagon	24.2% at 48 weeks (Phase 2)	Phase 3 ongoing (not approved)

Trial sources: STEP-1 (NEJM 2021); SURMOUNT-1 (NEJM 2022); Jastreboff et al. (NEJM 2023).

Why glucagon agonism matters

Semaglutide and tirzepatide reduce weight primarily through appetite suppression and slowed gastric emptying. Retatrutide adds glucagon receptor activation, which is proposed to increase basal metabolic rate and hepatic lipid oxidation, so the body burns fat more efficiently rather than just consuming less (Coskun et al., Cell Metabolism 2022). This third mechanism is offered as an explanation for why the Phase 2 weight-loss curves had not clearly plateaued at 48 weeks, suggesting the potential for further loss with continued dosing.

In contrast, a fair counter-perspective: semaglutide and tirzepatide carry full regulatory approval and longer real-world safety records. Retatrutide's stronger trial efficacy comes with the trade-off of unfinished Phase 3 data.

Local options include HD Labs Semaglutide 10 (single agonist), the Body Pharm Tirzepatide 60 Pen and HD Labs Tirzepatide 30 (dual agonist), or the Body Pharm Retatrutide 32 Pen (triple agonist, pen format).

Buy Retatrutide 10mg in South Africa

Retatrutide 10 mg is in stock at Beskinny.store at R1,500 per vial, with no minimum order quantity and shipping nationwide across South Africa. Each vial ships with 2 ml of bacteriostatic water included — no separate diluent purchase required, so you can reconstitute as soon as your order arrives. Pricing reflects rates current at the publication date above and may change.

Vial or pen — which format?

For a pre-filled, pre-measured device over manual reconstitution, the Body Pharm Retatrutide 32 Pen delivers the same compound in pen format and ships from local stock. Vials remain the most cost-efficient option per milligram because they avoid the device manufacturing premium. Pens trade a small price premium for dosing convenience.

Regulatory note

Retatrutide is not registered with SAHPRA (South African Health Products Regulatory Authority) for clinical use, as the compound remains in Phase 3 trials globally (SAHPRA Registered Health Products; ClinicalTrials.gov NCT06383390). Suppliers provide the product for research and personal use only. Buyers concerned about legal status should note that personal possession of unregistered peptides carries regulatory risk in South Africa. Consult a qualified healthcare provider before commencing any peptide protocol.

Frequently Asked Questions About Retatrutide 10mg

Quick answers to the most common questions buyers ask before their first vial:

1. How long does a 10 mg vial last? Reconstituted with 2 ml bacteriostatic water, the vial yields 5 mg per ml. A 2 mg starting dose draws 0.4 ml — roughly 5 injections per vial. A 4 mg dose draws 0.8 ml — approximately 2 injections per vial.
2. Does retatrutide need refrigeration? The lyophilised vial stores at -20°C long-term or 2–8°C short-term. Once reconstituted, keep the solution refrigerated at 2–8°C, protected from light, and use within 28 days.
3. Is retatrutide approved or legal in South Africa? SAHPRA has not registered retatrutide, and the compound remains in Phase 3 trials globally (ClinicalTrials.gov NCT06383390). Suppliers provide it for research and personal use only.
4. Can I use retatrutide without a doctor? Not recommended. Dose titration, gastrointestinal side-effect management, and cardiovascular monitoring (the trial recorded dose-dependent heart-rate increases that peaked at 24 weeks) require medical oversight (Jastreboff et al., NEJM 2023).
5. How does retatrutide compare to Ozempic? Retatrutide activates three receptors (GLP-1, GIP, glucagon) versus semaglutide's one. In separate trials, the retatrutide 12 mg arm reached 24.2% mean weight loss at 48 weeks versus 14.9% for semaglutide at 68 weeks. Users preferring a dual agonist can compare the Body Pharm Tirzepatide 60 Pen.

Related Products & Next Steps

Your next step: book a consultation with a licensed healthcare provider to confirm retatrutide suits your medical history, then choose the format that fits your dosing preference.

Order the Retatrutide 10mg vial at R1,500 for the most flexible dosing, or choose the Body Pharm Retatrutide 32 Pen for pre-measured convenience. Compare dual agonists via the Body Pharm Tirzepatide 60 Pen or HD Labs Tirzepatide 30, stack with NAD+ for mitochondrial support, or browse the full range of weight loss products.

References

1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023.
2. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 2022.
3. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes), NCT06383390. ClinicalTrials.gov, 2024.
4. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021.
5. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
6. Registered Health Products. South African Health Products Regulatory Authority (SAHPRA).